Koios Medical has secured the European CE Mark for its thyroid and breast cancer diagnosis ultrasound software.
The software incorporates data from 55 sites to support quick and accurate diagnosis, automate reporting, and reduce time to treatment, the company said. It is cleared by the U.S. Food and Drug Administration (FDA) and has been available in the U.S. since late 2021; this year, it was assigned CPT Category III billing codes.
